TY - JOUR
T1 - Death-associated protein kinase increases glycolytic rate through binding and activation of pyruvate kinase
AU - Mor, Inbal
AU - Carlessi, Rodrigo
AU - Ast, Tslil
AU - Feinstein, E.
AU - Kimchi, Adi
N1 - Flight Attendant Medical Research Institute; European Union; Israel Science FoundationWe thank Dr Shani Bialik for critical reading of the manuscript. GFP-PKM2-containing plasmid was the kind gift of A Ullrich (Max Planck Institute, Martinsried, Germany). A549 cells were the kind gift of M Oren (Weizmann Institute of Science, Rehovot, Israel). This work was supported by the Center of Excellence grant from the Flight Attendant Medical Research Institute, by a grant from the European Union FP7 to APO-SYS and by a grant from the Israel Science Foundation. AK is the incumbent of Helena Rubinstein Chair of Cancer Research.
PY - 2012/2
Y1 - 2012/2
N2 - Death-associated protein kinase (DAPk), a multi-domain serine/threonine kinase, regulates numerous cell death mechanisms and harbors tumor suppressor functions. In this study, we report that DAPk directly binds and functionally activates pyruvate kinase M2 (PKM2), a key glycolytic enzyme, which contributes to the regulation of cancer cell metabolism. PKM2 was identified as a novel binding partner of DAPk by a yeast two-hybrid screen. This interaction was validated in vitro by enzyme-linked immunosorbent assay using purified proteins and in vivo by co-immunoprecipitation of the two endogenous proteins from cells. In vitro interaction with full-length DAPk resulted in a significant increase in the activity of PKM2. Conversely, a fragment of DAPk harboring only the functional kinase domain (KD) could neither bind PKM2 in cells nor activate it in vitro. Indeed, DAPk failed to phosphorylate PKM2. Notably, transfection of cells, with a truncated DAPk lacking the KD, elevated endogenous PKM2 activity, suggesting that PKM2 activation by DAPk occurs independently of its kinase activity. DAPk-transfected cells displayed changes in glycolytic activity, as reflected by elevated lactate production, whereas glucose uptake remained unaltered. A mild reduction in cell proliferation was detected as well in these transfected cells. Altogether, this work identifies a new role for DAPk as a metabolic regulator, suggesting the concept of direct interactions between a tumor suppressor and a key glycolytic enzyme to limit cell growth. Moreover, the work documents a unique function of DAPk that is independent of its catalytic activity and a novel mechanism to activate PKM2 by protein-protein interaction. Oncogene (2012) 31, 683-693; doi:10.1038/onc.2011.264; published online 4 July 2011
AB - Death-associated protein kinase (DAPk), a multi-domain serine/threonine kinase, regulates numerous cell death mechanisms and harbors tumor suppressor functions. In this study, we report that DAPk directly binds and functionally activates pyruvate kinase M2 (PKM2), a key glycolytic enzyme, which contributes to the regulation of cancer cell metabolism. PKM2 was identified as a novel binding partner of DAPk by a yeast two-hybrid screen. This interaction was validated in vitro by enzyme-linked immunosorbent assay using purified proteins and in vivo by co-immunoprecipitation of the two endogenous proteins from cells. In vitro interaction with full-length DAPk resulted in a significant increase in the activity of PKM2. Conversely, a fragment of DAPk harboring only the functional kinase domain (KD) could neither bind PKM2 in cells nor activate it in vitro. Indeed, DAPk failed to phosphorylate PKM2. Notably, transfection of cells, with a truncated DAPk lacking the KD, elevated endogenous PKM2 activity, suggesting that PKM2 activation by DAPk occurs independently of its kinase activity. DAPk-transfected cells displayed changes in glycolytic activity, as reflected by elevated lactate production, whereas glucose uptake remained unaltered. A mild reduction in cell proliferation was detected as well in these transfected cells. Altogether, this work identifies a new role for DAPk as a metabolic regulator, suggesting the concept of direct interactions between a tumor suppressor and a key glycolytic enzyme to limit cell growth. Moreover, the work documents a unique function of DAPk that is independent of its catalytic activity and a novel mechanism to activate PKM2 by protein-protein interaction. Oncogene (2012) 31, 683-693; doi:10.1038/onc.2011.264; published online 4 July 2011
KW - DAPk
KW - PKM2
KW - cancer metabolism
KW - glycolysis
UR - http://www.scopus.com/inward/record.url?scp=84856951833&partnerID=8YFLogxK
U2 - https://doi.org/10.1038/onc.2011.264
DO - https://doi.org/10.1038/onc.2011.264
M3 - مقالة
C2 - 21725354
SN - 0950-9232
VL - 31
SP - 683
EP - 693
JO - Oncogene
JF - Oncogene
IS - 6
ER -